Russell Investments Group Ltd. Increases Stake in Henry Schein, Inc. (NASDAQ:HSIC)

Russell Investments Group Ltd. raised its holdings in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 45.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 345,731 shares of the company's stock after acquiring an additional 108,258 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.27% of Henry Schein worth $26,180,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Baystate Wealth Management LLC boosted its stake in shares of Henry Schein by 2,500.0% in the 3rd quarter. Baystate Wealth Management LLC now owns 520 shares of the company's stock valued at $39,000 after purchasing an additional 500 shares during the last quarter. McGlone Suttner Wealth Management Inc. bought a new position in Henry Schein during the fourth quarter worth $39,000. Neo Ivy Capital Management bought a new position in Henry Schein during the third quarter worth $46,000. Covestor Ltd boosted its stake in Henry Schein by 22.8% during the third quarter. Covestor Ltd now owns 1,367 shares of the company's stock worth $102,000 after acquiring an additional 254 shares in the last quarter. Finally, GAMMA Investing LLC bought a new position in Henry Schein during the fourth quarter worth $115,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Price Performance

Shares of Henry Schein stock traded down $0.18 during trading on Thursday, hitting $68.60. The stock had a trading volume of 1,318,897 shares, compared to its average volume of 1,083,691. The firm has a market cap of $8.81 billion, a price-to-earnings ratio of 21.78, a P/E/G ratio of 1.72 and a beta of 0.87. Henry Schein, Inc. has a 12 month low of $60.01 and a 12 month high of $82.63. The business's 50-day moving average is $73.70 and its 200 day moving average is $72.33. The company has a current ratio of 1.67, a quick ratio of 1.00 and a debt-to-equity ratio of 0.45.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.04). The firm had revenue of $3.02 billion during the quarter, compared to the consensus estimate of $3 billion. Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The company's revenue for the quarter was down 10.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.21 EPS. As a group, sell-side analysts anticipate that Henry Schein, Inc. will post 5.07 earnings per share for the current year.

Insider Activity at Henry Schein

In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the company's stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the sale, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at $5,430,462.24. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the sale, the insider now owns 209,562 shares of the company's stock, valued at $15,585,125.94. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

HSIC has been the topic of several research analyst reports. Barrington Research increased their target price on shares of Henry Schein from $82.00 to $90.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 28th. Evercore ISI upped their price objective on shares of Henry Schein from $79.00 to $83.00 and gave the stock an "in-line" rating in a report on Wednesday, February 28th. Jefferies Financial Group upped their price objective on shares of Henry Schein from $74.00 to $81.00 and gave the stock a "hold" rating in a report on Wednesday, March 6th. Piper Sandler upped their price objective on shares of Henry Schein from $78.00 to $86.00 and gave the stock an "overweight" rating in a report on Monday, February 26th. Finally, JPMorgan Chase & Co. increased their target price on shares of Henry Schein from $82.00 to $88.00 and gave the company an "overweight" rating in a report on Wednesday, March 6th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Henry Schein currently has a consensus rating of "Hold" and a consensus target price of $81.09.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.